AUS
NZ
UK
CA
USA
IND
Source: Guschenkova, Shutterstock
Summary
- Stocks of Second Sight Medical rallied about 400 per cent in the last couple of sessions.
- Shares of the eye products developer have traded with an average volume of 106 million in the last 10 days.
- Another US-based medical firm’s stock rocketed approximately 37 per cent on Monday following the release of peer-reviewed study.
Second Sight Medical Products (EYES:US or NASDAQ: EYES) flew as much as 103.28 per cent on Monday, March 8, as its Argus 2s Retinal Prosthesis System received the US Food and Drug Administration (FDA) approval on Friday.
OpGen (OPGN:US or NASDAQ: OPGN) stock, meanwhile, zoomed nearly 37 per cent on Monday following effective results from its rapid diagnostic test for COVID-19-pneumonia co-infections.
Let us delve into these two NASDAQ-listed healthcare stocks’ performances:
Second Sight Medical Products (EYES:US or NASDAQ: EYES)
On Monday, the medical stock crossed its 52-week high of US$ 9.89 by more than 19 per cent. Currently posting a share price of US$ 11.77, it saw almost 321 million shares change hands yesterday. The eye specialist firm has 23.21 million outstanding shares on the NASDAQ.
On March 5, the stock skyrocketed over 300 per cent on the back of its latest FDA approval. Consequently, it soared over 529 per cent year-to-date (YTD) and its one-year return has grown 195.73 per cent, topping the NASDAQ Composite Index that has risen 101.13 in one year. Second Sight Medical has a current market cap of US$ 273.22 million.
The eyes-related device manufacturer is likely to announce its financial results on March 18.
Image Source: Kalkine Group @2021
OpGen (OPGN:US or NASDAQ: OPGN)
The results of OpGen’s Unyvero Hospitalized Pneumonia (HPN) panel study has been published in the European Journal of Clinical Microbiology & Infectious Diseases. This panel diagnoses COVID-19 patients who have also been suffering from pneumonia.
The medical research firm’s stock has been recovering from the COVID-19 meltdown, and it has a current price of US$ 2.68. It rebounded 76.32 per cent from a 52-week low share price of US$ 1.52 (plummeted on March 12, 2020). However, it has declined by almost 12 per cent in one-year and is down 53.47 per cent from its 52-week high of US$ 5.76 (recorded on March 16, 2020).
In its interim fourth quarter of 2020 results, the company reported a revenue of nearly US$ 1.3 million, up from US$ 0.8 million in the fourth quarter of 2019.
OpGen, which raised US$ 35.3 million last year, posted available cash of US$ 13.3 million as of December 31, 2020.
